Analogy 1: A clinical-stage biotech, similar to an early Biogen or Eli Lilly, primarily developing experimental drugs for neurological diseases like Alzheimer's.

Analogy 2: Think of it as a drug R&D company aiming for breakthrough treatments for severe conditions such as Alzheimer's and liver disease, much like a startup Regeneron or Vertex.

• BIV201: A drug therapy in clinical trials for the treatment of ascites due to chronic liver cirrhosis.
• NE3107: A drug therapy in various stages of development for Alzheimer's disease, Parkinson's disease, multiple myeloma, and prostate cancer.

BioVie Inc. (BIVI) is a clinical-stage biotechnology company focused on the discovery and development of drug therapies. As per the provided description, its products (BIV201 and NE3107) are currently in various phases of clinical trials (Phase I, Phase IIa, Phase III) or pre-clinical stages. This means the company's drug therapies are not yet commercialized or available for sale to the public or to other companies.

Therefore, BioVie Inc. does not currently have major customers, nor does it sell primarily to other companies or directly to individuals in the traditional sense of a commercialized entity. Its primary activities are research and development and advancing its drug candidates through clinical trials towards regulatory approval.

Cuong Do, President & Chief Executive Officer

Mr. Do currently serves as the President and CEO of BioVie Inc.. Prior to his appointment with BioVie, he was the President of Samsung Global Strategy Group, where he helped set the strategic direction for Samsung Group's diverse business portfolio. He also served as the Chief Strategy Officer for Merck, a leading U.S. pharmaceuticals company. Mr. Do was a senior partner at McKinsey & Company for 17 years, contributing to the development of their healthcare, high tech, and corporate finance practices. He is an active entrepreneur who founded Callidus Biopharma, a biotech company acquired by Amicus Therapeutics in 2013, and also founded Lysodel Therapeutics and M6P Therapeutics.

Wendy Kim, Chief Financial Officer

Ms. Kim is the Chief Financial Officer of BioVie Inc.. She possesses over 25 years of experience in accounting and finance. As a CFO prior to BioVie, she managed corporate finance and operational groups, successfully completed 8 M&A transactions, secured bank financings, developed and implemented new business strategies, managed risk, and implemented new financial policies and procedures. She also spent 8 years as a public accountant in the SEC Department of BDO USA LLP.

Joseph M. Palumbo, Executive Vice President, Research & Development and Chief Medical Officer

Dr. Palumbo serves as the Executive Vice President, Research & Development and Chief Medical Officer at BioVie. His experience includes developing drugs for central nervous system (CNS) conditions at companies such as Johnson & Johnson and Mitsubishi.

Clarence N. Ahlem, Senior Vice President Operations

Mr. Ahlem is the Senior Vice President of Operations at BioVie.

David Morse, Chief Regulatory Officer and Senior Vice President

Dr. Morse holds the position of Chief Regulatory Officer and Senior Vice President at BioVie. He has over 35 years of experience in pharmaceutical development and Regulatory Affairs. Prior to BioVie, he served as Vice President of Global Regulatory Affairs and Vice President of Regulatory Strategy for several top-tier contract research organization (CRO) services industry corporations. His background also includes roles as an independent consultant, Associate Director at the U.S. Food and Drug Administration (FDA), and Laboratory Director in translational medicine research settings. Dr. Morse has a history of successful application strategy development for multinational submissions to various regulatory authorities, resulting in over a dozen successful regulatory authority filings and market application approvals.

BioVie Inc. (BIVI), a clinical-stage biotechnology company, faces several significant risks primarily stemming from the uncertain and complex nature of drug development.

1. Clinical Trial Failure and Operational Misconduct: The most significant risk to BioVie's business is the potential for clinical trial failures or operational issues during trials, which can severely impact product development and investor confidence. This risk has recently materialized with the Phase III Alzheimer's disease trial for its lead candidate, NE3107, which failed to meet its co-primary endpoints. The company attributed this failure to "significant deviation from protocol and Good Clinical Practice violations" at 15 of its 39 trial sites, leading to the exclusion of a substantial portion of the patient data. This operational mismanagement during a critical late-stage trial directly led to a significant drop in BioVie's stock price.
2. Financial Instability and Going Concern Uncertainty: As a clinical-stage company with no material commercial revenue, BioVie is subject to substantial financial risk. The company consistently reports net losses due to its significant research and development expenses. BioVie has explicitly disclosed "substantial doubt about its ability to continue as a going concern" without securing additional financing. This reliance on external funding, coupled with the capital-intensive nature of drug development and the recent Phase III trial setback, makes its financial position precarious.
3. Regulatory Scrutiny and Litigation: Arising from the issues in the NE3107 Phase III trial, BioVie faces potential regulatory challenges and ongoing litigation. The company referred the problematic trial sites to the FDA's investigations unit, indicating potential regulatory scrutiny. Furthermore, BioVie is currently facing a securities fraud class action lawsuit. The lawsuit alleges that the company made misleading statements and failed to adequately disclose the risks of protocol deviations and oversight challenges during the Phase III trial, especially in the context of the COVID-19 pandemic. Such legal and regulatory pressures can incur significant costs and divert management's focus from core development activities.

Addressable Markets for BioVie (BIVI) Products

BioVie Inc. (BIVI) is developing drug therapies for several significant medical conditions. The addressable markets for their main products are as follows:

• BIV201 for ascites due to chronic liver cirrhosis: The U.S. commercial opportunity for refractory ascites is estimated at $1.6 billion annually, with a global peak annual sales potential also at $1.6 billion. More broadly, the total Ascites market size in the U.S. due to cirrhosis was estimated to be more than USD 800 million in 2023. The global ascites market is projected to grow from USD 3.9 billion in 2024 to USD 5.9 billion by 2030.
• NE3107 for Alzheimer's disease: The U.S. market for Alzheimer's disease is estimated at $30 billion. Globally, the Alzheimer's disease market is expected to grow from $2.4 billion in 2023 to $17 billion by 2033 across eight major markets (China, France, Germany, Japan, Italy, Spain, the UK, and the US). Another estimate places the global Alzheimer's therapeutics market size at USD 6.49 billion in 2025, projected to reach approximately USD 33.62 billion by 2034.
• NE3107 for Parkinson's disease: The U.S. market for Parkinson's disease, as an additional upside for NE3107, is estimated at $3 billion. The global Parkinson's disease treatment market size was estimated at USD 5.65 billion in 2024 and is expected to reach USD 7.58 billion by 2030. The Parkinson's Disease market size in the U.S. was approximately USD 1,883 million in 2023.
• NE3107 for multiple myeloma: The global multiple myeloma market size is projected to grow from USD 27.75 billion in 2024 to approximately USD 49.89 billion by 2034. Another source estimates the global market size at USD 29.24 billion in 2025, growing to USD 49.79 billion by 2034.
• NE3107 for prostate cancer: The global prostate cancer market size is projected to reach approximately USD 28.83 billion by 2035, with an estimated value of USD 12.88 billion in 2025. Another estimate indicates the global prostate cancer market is expected to reach a valuation of USD 30,287.8 million by 2033, from USD 13,717.2 million in 2024.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company with several drug candidates in development that are expected to drive future revenue growth over the next 2-3 years. The company's revenue generation is contingent upon successful clinical trial outcomes, regulatory approvals, and potential commercialization or strategic partnerships for its pipeline assets.

Here are the key expected drivers of future revenue growth:

1. Commercialization of NE3107 for Parkinson's Disease: BioVie's bezisterim (NE3107) has emerged as a lead value driver, particularly in Parkinson's disease. The company expects topline data from its SUNRISE-PD study in April or May 2026, and mid-2026. Given its Fast Track designation, successful completion of clinical trials and subsequent regulatory approval could lead to significant revenue generation. BioVie's CEO estimates the Parkinson's market alone could represent an annual sales opportunity of $3-5 billion in the U.S.
2. Potential Approval and Commercialization of NE3107 for Alzheimer's Disease: BioVie has completed a Phase 3 trial for NE3107 in mild to moderate Alzheimer's disease. While the initial primary efficacy endpoint was not met due to site exclusions, positive trends in per-protocol patients suggest biological activity, and the company may continue enrolling patients to achieve statistical significance for registration purposes. The Alzheimer's market is a substantial opportunity, with the CEO suggesting it could be a $30 billion indication for NE3107. Achieving regulatory approval would be a transformative revenue driver.
3. Advancement and Commercialization of BIV201 for Ascites: BIV201, an Orphan Drug candidate for ascites due to chronic liver cirrhosis, has received FDA Fast Track designation and guidance for a Phase 3 clinical trial. This positions BIV201 as a potential first-in-class therapy for a condition with no currently approved treatments, which could secure 7 years of market exclusivity in the U.S. if approved.
4. Potential Commercialization of NE3107 for Long COVID: BioVie is conducting a 200-patient trial for NE3107 in long COVID, supported by a $13 million non-dilutive grant, with topline data anticipated in mid-2026. The company projects that this indication could represent a $20-30 billion market opportunity.
5. Strategic Partnerships: Analyst commentary indicates that BioVie's first meaningful revenue, projected to be around $12.81 million in 2025, is likely to come from partnerships or early NE3107 approvals. Collaborations with larger pharmaceutical companies for further development, manufacturing, or commercialization of its pipeline assets could provide upfront payments, milestone payments, and royalties, contributing to revenue growth.

Share Repurchases

BioVie has not made significant share repurchases over the last 3-5 years, as indicated by a negative buyback yield, which suggests dilution rather than repurchases.

Share Issuance

• In August 2025, BioVie completed a public offering, selling 5.62 million Units and 380,000 Pre-Funded Units, which generated approximately $10.4 million in net proceeds. Each Unit included one share of Class A Common Stock and one Warrant.
• In October 2024, the company priced a registered direct offering of 2,667,000 shares of common stock at $2.25 per share, resulting in gross proceeds of $6,000,750. Unregistered warrants to purchase up to 2,667,000 shares were also issued in a concurrent private placement.
• A one-for-ten (1:10) reverse stock split of the Company's Class A common stock became effective on July 7, 2025.

Inbound Investments

• In April 2024, BioVie received a $13.1 million grant from the U.S. Department of Defense (DoD) to fund research for bezisterim in Long COVID.

Outbound Investments

• In June 2021, BioVie acquired the biopharmaceutical assets of NeurMedix, Inc. The consideration for this acquisition included 8,361,308 newly issued BioVie shares and approximately $3.0 million in cash at closing.
• An additional $7.3 million cash payment is contingent upon the pivotal Phase 3 clinical trial for NeurMedix's Alzheimer's drug candidate meeting its primary endpoint(s) and the successful raise of $50 million of new capital.

Capital Expenditures

Information regarding significant capital expenditures in terms of dollar value or primary focus for BioVie over the last 3-5 years is not readily available in the provided search results.